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Norovirus (NoV) is the major causative 
agent of acute viral gastroenteritis world-
wide. Based on genetic analyses, human 
NoV strains have been classified into at least 
three genogroups: genogroup I (GI), GII, 
and GIV, which contain at least 15, 18, and 
1 genotypes, respectively (Kageyama et al., 
2004). Notably, these NoV genotypes are 
morphologically similar to one another but 
differ antigenically (Kapikian, 1996; Estes 
et al., 1997; Hansman et al., 2006). Since no 
cell culture system has been developed yet, 
molecular analyses to elucidate the mecha-
nisms underlying infection or productive 
replication have been stalled until recently. 
The primary NoV replication site in 
humans is unknown, but intestinal biopsy 
from volunteer who became ill following 
oral administration of NoV exhibited his-
topathologic lesions, in which the villi of the 
proximal small intestine were blunted (Agus 
et al., 1973). More than 30 years ago, the 
initial NoV challenge studies conducted in 
volunteers found that a subset of individu-
als was repeatedly susceptible to NoV infec-
tion, whereas a second subset was repeatedly 
resistant to infection (Parrino et al., 1977). 
A genetic factor, possibly a receptor, was 
hypothesized to affect the susceptibility of 
an individual to NoV infection. Recently, 
a mechanism that explains the suscepti-
bility or resistance to NoV infection has 
been identified; namely, NoV attaches to 
histo-blood group antigens (HBGAs) on 
potential host cells in the gut (Lindesmith 
et al., 2003).
HBGAs are structurally related oli-
gosaccharides that include ABH anti-
gens and Lewis (Le) antigens (Figure 1). 
Polymorphisms in the ABH antigens are 
induced by variations in the core struc-
ture. Type 1 chain ABH antigens are widely 
expressed in endodermally derived tissues 
such as the lining epithelia and the glandu-
lar epithelia (Oriol et al., 1986). Meanwhile, 
type 2 chain ABH  antigens are found pri-
of approximately 58 kDa are generated 
and self-assembled into VLPs (Xi et al., 
1990; Jiang et al., 1993). Though artificial, 
these VLPs are morphologically and anti-
genically similar to those of the respective 
native virions (Jiang et al., 1992; Green 
et al., 1993; Prasad et al., 1994, 1999). VP1 
has two major domains: a shell (S) domain, 
which forms the core of the icosahedral shell 
(Bertolotti-Ciarlet et al., 2002), and a pro-
truding (P) domain, which forms arches 
extending from the shell and is responsible 
for host interactions (Tan et al., 2004, 2011; 
Tan and Jiang, 2005a,b, 2007). The associa-
tion and dissociation kinetics for NoV VLPs 
binding to HBGAs were measured with SPR 
experiments (Choi et al., 2008; Shirato 
et al., 2008), which allowed us to visualize 
marily in ecto- or meso-dermally derived 
tissues, including skin and erythrocytes 
(Hakomori, 1981; Dabelsteen et al., 1982; 
Oriol et al., 1986). In the human gastroduo-
denal junction, type 1 structures are found 
exclusively at the level of the surface epi-
thelia, whereas type 2 structures are pref-
erentially found at the glandular level 
(Mollicone et al., 1985).
Details of the NoV recognition of 
HBGAs were clarified with in vitro experi-
ments, enzyme-linked immunosorbent 
assays (ELISAs), and surface plasmon reso-
nance (SPR) experiments using virus-like 
particles (VLPs), as well as crystallization 
studies using P domains. When the NoV 
VP1 gene, which encodes a capsid protein, 
is expressed in insect cells, capsid proteins 
Abbreviations: Fuc, fucose; Gal, galactose;  GalNAc, 
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Figure 1 | NoV recognition sites on histo-blood group antigens. The structure represents a 
pentasaccharide as the final product (ALeb or BLeb: in the case of BLeb, the terminal residue is Gal.) of 
human HBGA synthesis. H types 1 (Fucα1-2Galβ1-3GlcNAcβ1-) and 2 (Fucα1-2Galβ1-4GlcNAcβ1-) are the 
terminal moieties expressed in histo-blood group type O individuals. However, in A, B, and AB individuals the 
H antigens are further modified by enzymes that transfer N-acetylgalactosamine (GalNAc, type A), Gal (type 
B), or either carbohydrate (type AB) to the terminal Gal residue of an H antigen in an α3 linkage. For NoV 
recognition site 1 on HBGAs, the majority of GI NoVs interact with the A [GalNAcα1-3(Fucα1-2)Galβ1-] and 
Lea [Galβ1-3(Fucα1-4)GlcNAcβ1-] antigens, whereas GII NoVs exhibit more diverse HBGA-binding patterns, 
such as for the B [Galα1-3(Fucα1-2)Galβ1-] antigen. For recognition site 2, NoV VLPs are able to distinguish 
between the type 1 (Galβ1-3GlcNAcβ1-) and type 2 (Galβ1-4GlcNAcβ1-) core structures of HBGAs and bind 
more tightly to the type 1 carbohydrates than to the type 2 carbohydrates.
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important  factors in  determining the host 
specificity of NoV, although it remains 
unclear whether they function as the pri-
mary receptor or enhance NoV infectivity 
and/or attachment to a common cellular 
receptor. Since NoV comprises a number 
of antigenically diverse groups, identifica-
tion of the common NoV-binding epitopes 
on host cells, if any, should be useful in the 
development of possible antiviral agents.
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